Tema Oncology ETF (CANC) is a healthcare and biotech ETF. As of October 9, 2026, ETF Copilot scores CANC 5.9 out of 10 — highest on Growth (8.9), lowest on Quality (2.1). Its ten largest holdings are 41% of the fund.
What stands out in CANC's data
US and European oncology stocks, from drugmakers to biotech firms.
Returned more over three years than the typical health-sector fund — a run that outpaced the group.
A 22% annualized three-year return tops the 17% category median. The fund charges 1.0% in expenses and holds EBITDA margin of 22.1%.
A thematic sleeve for portfolios seeking direct exposure to oncology-focused healthcare.
Why did CANC move this week? It fell 0.5% in the week to October 9, 2026 — Revolution Medicines and Enliven Therapeutics drove it
CANC fell 0.5% in the week to October 9, 2026. The holdings that moved it most were Revolution Medicines (−8.2%), Enliven Therapeutics (−12.8%) and Immunome (−6.5%); Genmab A/S (+6.7%) pushed the other way.
How is CANC rated? ETF Copilot scores Tema Oncology ETF (CANC) 5.9 out of 10
As of October 9, 2026, ETF Copilot scores Tema Oncology ETF (CANC) 5.9 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 5.9 / 10
- Growth: 8.9 / 10
- Risk: 2.8 / 10
- Quality: 2.1 / 10
- Return: 7.7 / 10
What's inside CANC?
What's inside CANC: Size (Large 41%, Mid 27%, Small 32%); Geography (International 21%, US 79%).
What are CANC's top holdings? The ten largest are 41% of the fund
Revolution Medicines, Merck, Eli Lilly, Cogent Biosciences, Novartis, Genmab A/S, Abbvie, Beigene, Exelixis and Halozyme Therapeutics are CANC's largest holdings, in that order.
Less concentrated than 64% of Health & Biotech ETFs.
Half of CANC's weight sits in its 14 largest positions, and once those weights are taken into account it behaves like 35 equally weighted holdings.
What is CANC's expense ratio? 0.99% a year
As of October 9, 2026, CANC charges 0.99% a year, yields 0.05% and holds $202M in assets across 59 positions.
| Measure | CANC |
|---|---|
| Expense ratio | 0.99% |
| Dividend yield | 0.05% |
| Assets under management | $202M |
| Holdings | 59 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
Cite this
ETF Copilot, “Tema Oncology ETF (CANC) scores and holdings analysis”, as of October 9, 2026.
https://etf-copilot.com/etf/canc
ETF Copilot Pro unlocks CANC's price and what each holding weighs.
Try Pro free →